Loxo
Early studies of KRAS inhibitors from Loxo Oncology, Genentech, and Innovent suggest newer drugs have activity in KRAS G12C-resistant patients.
Tempus, Lilly Ink Partnership to Offer No-Cost NGS for Advanced NSCLC Patients
Lilly will cover the cost of Tempus' broad-based sequencing tests for advanced non-small cell lung cancer patients to improve biomarker testing access.
Eli Lilly, Foghorn Ink Deal to Advance Therapies Against BRG1-Mutated Cancer, Undisclosed Target
In the deal, Foghorn is receiving $300 million in cash plus an $80 million equity investment and is eligible for further royalties and milestone-based payments.
FDA Approves Eli Lilly's Verzenio as Adjuvant Therapy for High-Risk, Early Breast Cancer Patients
The decision follows results from the monarchE trial, in which the drug with endocrine therapy benefited early-stage breast cancer patients with a high Ki-67 score.
In Brief This Week: AstraZeneca, Amgen, Oncocyte, Rain Therapeutics
News items for the week of April 19, 2021
Apr 2, 2019